Director General of Mexico's National Institute of Genomic
Medicine says genetic studies crucial for health of Mexican and
U.S. Hispanics
PHOENIX, Ariz. - June 5, 2009 - Differences in the DNA among
Mexico's 65 ethnic populations must be identified to significantly
advance that developing nation's public health, a top Mexican
official said at the 2009 Scientific Retreat of the Translational
Genomic Research Institute (TGen).
Dr. Gerardo Jimenez-Sanchez, M.D., Director General of Mexico's
National Institute of Genomic Medicine (INMEGEN), told more than
300 assembled scientists that such information might one day
explain why a greater proportion of Mexicans, than those in other
countries, got sick and died during the recent worldwide outbreak
of swine flu.
Dr. Gerardo Jimenez-Sanchez, Director General of Mexico's National
Institute of Genomic Medicine (INMEGEN)
"This is when science can make a life-changing impact," Dr.
Jimenez-Sanchez said Thursday, June 4, during the keynote address
of the day-long conference at the Phoenix Convention Center.
Discovering the unique genetic biomarkers within Mexico's
surprisingly diverse populations could lead to development of more
specific, safer and effective drugs to combat such disabling
conditions as diabetes, heart disease and cancer - especially as
Mexico moves to join the ranks of the world's developed nations, he
said.
Currently, many drugs sold in Mexico are manufactured in Europe,
and are designed for generic populations, Dr. Jimenez-Sanchez said.
"We are believers in personalized medicine. We need to develop our
own (scientific) tools and our own products through genomic
medicine."
Dr. Jeffrey Trent, TGen's President and Research Director, joined
Dr. Jimenez-Sanchez in predicting that genomic research would not
only benefit Mexicans, but also would improve the health of
Hispanics living in the U.S.
"If we are not developing drugs specifically for individuals based
on their genetic make-up, we might not be giving them the right
drugs at the right time in the right dosages," said Dr. Trent, who
until TGen's start in 2002 held a similar U.S. post to Dr.
Jimenez-Sanchez's position in Mexico. Dr. Trent is the former
Scientific Director of the National Human Genome Research Institute
at the National Institutes of Health in Bethesda, Maryland.
Genetic research has significant health implications for border
states like Arizona, where nearly 1 in 3 residents are Latino, said
Dr. Trent, who also joined Dr. Jimenez-Sanchez in emphasizing the
essential importance of cooperative studies between U.S. and
Mexican researchers.
For example, as part of TGen's first international collaboration
agreement signed in 2003, TGen and INMEGEN scientists are searching
for mutations associated with Age-related Macular Degeneration
(AMD), which gradually destroys sharp, central vision, preventing
such common and essential tasks as reading and driving.
Dr. Jimenez-Sanchez said a landmark INMEGEN study released in May
traced the proportional racial and ethnic differences among
Mexicans, including evidence of the migrations of Asians to the
Americas during the last ice age more than 10,000 years ago, and
the migrations of Europeans - especially from Spain - as well as
Africans, beginning more than 500 years ago.
The findings of the Mexican Genome Diversity Project, published in
the Proceedings of the National Academy of Sciences (PNAS),
analyzed the genetic composition of 300 Mestizos, or Latin
Americans of mostly mixed European and Amerindian populations. Such
studies are part of a global search for health-related genes
throughout humanity.
"This is not trivial," Dr. Jimenez-Sanchez emphasized in
describing the health effects of what are often infinitesimal
differences in the human genome, the more than 3-billion base pairs
of DNA that make us who we are. "This really is the tip of the
iceberg."
Jimenez-Sanchez noted that it was just 10 years ago that
scientists worldwide began to identify single-nucleotide
polymorphisms (SNPs) that were useful in discovering the molecular
basis of complex disorders and disease.
Already, he said, Mexican scientists are looking at Ancestry
Informative Markers, or AIMs, to identify ways of diagnosing
thyroid, skin and lung cancers, and are zeroing in on a specific
gene that could help in the treatment of cardio-vascular
diseases.
Thursday's TGen Scientific Retreat was the institute's first
involving more than 40 scientists from the Van Andel Research
Institute in Grand Rapids, Mich., which will initiate an "Alliance
and Affiliation Agreement" with TGen later this year. This
strategic alliance is designed to enable both institutes to
maximize their worldwide contributions to science and health.
*
About Dr. Gerardo Jimenez-Sanchez
Dr. Gerardo Jimenez-Sanchez, Director General of Mexico's National
Institute of Genomic Medicine (INMEGEN), holds an M.D. and Ph.D. in
Human Genetics and Molecular Biology from Johns Hopkins University.
He is a certified Pediatrician and a member of: the National
Academy of Medicine, the American Society of Human Genetics, the
American Society of Gene Therapy, the Society for Inherited
Metabolic Disease, the European Society of Inborn Errors of
Metabolism, and Chairman of the Working Party on Biotechnology at
the international Organization for Economic Cooperation and
Development (OECD). His current research focuses on the study of
human disease-causing genes and the development of genomic medicine
in Mexico.
*
About INMEGEN
The Mexican government founded the National Institute of Genomic
Medicine (INMEGEN) to conduct world-class scientific research,
implement technological platforms and develop educational programs
in genomic medicine. For more information, and to see an
interactive version of the Mexican Genome Diversity Project, visit:
www.inmegen.gob.mx.
*
About TGen
The Translational Genomics Research Institute (TGen) is a Phoenix,
Arizona-based non-profit organization dedicated to conducting
groundbreaking research with life changing results. Research at
TGen is focused on helping patients with diseases such as cancer,
neurological disorders and diabetes. TGen is on the cutting edge of
translational research where investigators are able to unravel the
genetic components of common and complex diseases. Working with
collaborators in the scientific and medical communities, TGen
believes it can make a substantial contribution to the efficiency
and effectiveness of the translational process. TGen is affiliated
with the Van Andel Research Institute in Grand Rapids, Michigan.
For more information, visit: www.tgen.org.
Press Contact:
Steve Yozwiak
TGen Senior Science Writer
602-343-8704
[email protected]
# # #